Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 545

    1.

    Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

    Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E, Uhr J.

    Breast Cancer Res. 2007;9(5):R74.

    PMID:
    17963511
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.

    Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, Brandt B.

    Clin Cancer Res. 2006 Mar 15;12(6):1715-20.

    PMID:
    16551854
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

    Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

    J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.

    PMID:
    17954712
    [PubMed - indexed for MEDLINE]
    4.

    HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

    Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K.

    Breast Cancer Res Treat. 2010 Nov;124(2):403-12. Epub 2010 Sep 22.

    PMID:
    20859679
    [PubMed - indexed for MEDLINE]
    5.

    Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.

    Cao S, Li Y, Li J, Li CF, Zhang W, Yang ZQ, Meng SD.

    Oncol Rep. 2010 Feb;23(2):423-8.

    PMID:
    20043103
    [PubMed - indexed for MEDLINE]
    6.

    Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

    Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A.

    Breast Cancer Res Treat. 2009 Dec;118(3):523-30. Epub 2009 Jul 12.

    PMID:
    19597704
    [PubMed - indexed for MEDLINE]
    7.

    Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

    Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH.

    Breast Cancer Res Treat. 2011 Jul;128(1):155-63. Epub 2011 Apr 16.

    PMID:
    21499685
    [PubMed - indexed for MEDLINE]
    8.

    Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.

    Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP.

    Clin Breast Cancer. 2004 Jun;5(2):105-16. Review.

    PMID:
    15245613
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.

    Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A.

    Cancer. 2010 Jul 15;116(14):3330-7.

    PMID:
    20564098
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.

    Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL, Robertson JF.

    Breast Cancer Res. 2007;9(6):R75.

    PMID:
    17976236
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

    Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D.

    Ann Oncol. 2007 May;18(5):851-8. Epub 2007 Feb 14. Erratum in: Ann Oncol. 2007 Nov;18(11):1916.

    PMID:
    17301075
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.

    Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A.

    Breast Cancer Res Treat. 2009 Feb;113(3):501-7. Epub 2008 Mar 9.

    PMID:
    18327638
    [PubMed - indexed for MEDLINE]
    13.

    Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

    Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT.

    Clin Breast Cancer. 2010 Oct 1;10(5):392-7.

    PMID:
    20920984
    [PubMed - indexed for MEDLINE]
    14.

    Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.

    Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V.

    Breast Cancer Res. 2006;8(4):R36.

    PMID:
    16846533
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.

    Jensen BV, Johansen JS, Price PA.

    Clin Cancer Res. 2003 Oct 1;9(12):4423-34.

    PMID:
    14555515
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Changes of serum HER2 status during clinical course of metastatic breast cancer patients.

    Fehm T, Jäger W, Kraemer S, Sohn C, Solomayer-Meyberg G, Solomayer EF, Kurek R, Wallwiener D, Gebauer G.

    Anticancer Res. 2004 Nov-Dec;24(6):4205-10.

    PMID:
    15739264
    [PubMed - indexed for MEDLINE]
    17.

    Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.

    Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D.

    Breast Cancer Res Treat. 2009 Oct;117(3):525-34. Epub 2008 Nov 19. Erratum in: Breast Cancer Res Treat. 2009 Oct;117(3):539.

    PMID:
    19016323
    [PubMed - indexed for MEDLINE]
    18.

    Detection of circulating tumor cells in metastatic breast cancer patients.

    Sanislo L, Vertakova-Krakovska B, Kuliffay P, Brtko J, Galbava A, Galbavy S.

    Endocr Regul. 2011 Jul;45(3):113-24.

    PMID:
    21793623
    [PubMed - indexed for MEDLINE]
    19.

    High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.

    Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E.

    Cancer. 2007 Nov 15;110(10):2178-85.

    PMID:
    17926331
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

    Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN.

    Int J Biol Markers. 2009 Jan-Mar;24(1):1-10.

    PMID:
    19404916
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk